PDI, Inc. (NASDAQ:PDII)

CAPS Rating: No stars

A sales and marketing services company, which serves the biopharmaceutical and life sciences industries.

Results 1 - 3 of 3

Recs

0
Member Avatar skc0001 (< 20) Submitted: 5/14/2007 9:01:20 AM : Outperform Start Price: $10.03 PDII Score: -121.11

A Value Proposition

Recs

1
Member Avatar no1spec1al (< 20) Submitted: 4/22/2007 9:10:39 PM : Outperform Start Price: $9.40 PDII Score: -122.30

Trading below book value, new management. Their price was beaten down for loss of a large contract, but they've since picked up another. Not profitable at the moment, but with the company trading below book value your risks are pretty low. With the new sales director this stock can only get better.

Recs

0
Member Avatar NuvoRiche (78.96) Submitted: 4/17/2007 3:20:14 PM : Underperform Start Price: $9.50 PDII Score: +123.76

Provides outsourced sales & marketing force capability for Pharma companies, that can either replace or augment an in-house sales force. Currently beaten down by the loss of 3 major accounts as of Dec 06 (GSK, SNY, Astra-Zeneca) accounting for $126M (56%) of revenues. Forward EPS -1.46 for '07 and negative again for '08. President of Sales just "resigned" in 4/07, and a somewhat nebulous "long-term strategic plan" will be implemented in 2007. Major selling point on this stock is that as of 4/07 it's trading below book value (P/B 0.88) giving potentially a margin of safety. But who knows, turnarounds can work. So I'll give it a short-term thumbs down, but may offer a good value opportunity for a risk-tolerant LT buy-and-hold portfolio.

Results 1 - 3 of 3

Featured Broker Partners


Advertisement